GOOD DOCTOR ·
The company was established in
New clean factory
Successful applications of hyperthermic perfusion therapy
Independent Intellectual Property Rights
Xi'an Good Doctor Medical Technology Co., Ltd.
HYPERTHERMIC PERFUSION
Xi'an Good Doctor Medical Technology Co., Ltd.,it is a specialized medical technology company that has taken the lead in adopting continuous circulation hyperthermic perfusion chmotherapy technology at home and abroad.
The company focuses on the field of constant temperature continuous circulation hyperthermic perfusion chemotherapy technology, integrating new clinical technologies such as chest and abdominal chemotherapy and postoperative abdominal hyperthermic cleaning that have emerged in recent years. This technology can effectively prevent and treat cancer implantation metastasis after surgery, while also effectively controlling the cancerous effusion generated after metastasis. It fundamentally solves the problem of tumor postoperative metastasis and recurrent cancerous effusion, successfully solving a series of problems recognized by the medical community in clinical application, such as non-constant temperature, uneven heat distribution, and high incidence rate of adhesion during traditional intracavitary hyperthermic perfusion. It has significant scientificity, innovation, and clinical practicality.
Hyperthermic Perfusion Chemotherapy Equipment
GDPR-2100S
A hyperthermic perfusion chemotherapy equipment more suitable for applications in clinical departments
The hyperthermic perfusion chemotherapy equipment is a medical device that uses the principle of hyperthermic therapy to prevent implant metastasis and control cancerous effusion. This equipment uses the catheter directly placed during the operation or the drainage catheter indwelling after the operation to inject the perfusate into the body cavity after being automatically heated in the equipment. Under the full process dynamic detection and feedback adjustment of the computer, the perfusate is maintained at a treatment temperature of 42.5 ° C for 60 minutes, and heat-sensitive chemotherapy drugs can be added to achieve the synergistic effect of chemotherapy drugs and hyperthermia, effectively killing free cancer cells or small implanted metastatic cancer lesions. Combined with surgery, it can treat or prevent tumor metastasis, and when used alone, it can effectively control cancerous effusion, improve patients' quality and time of life.
Learn moreGood applicability
High security
Synergistic effect of drugs and hyperthermia
Good selectivity
Good operability
Hyperthermic Perfusion Chemotherapy Equipment
GDPR-2100T
A hyperthermic perfusion chemotherapy equipment more suitable for applications in clinical departments
The hyperthermic perfusion chemotherapy equipment is a medical device that uses the principle of hyperthermic therapy to prevent implant metastasis and control cancerous effusion. This equipment uses the catheter directly placed during the operation or the drainage catheter indwelling after the operation to inject the perfusate into the body cavity after being automatically heated in the equipment. Under the full process dynamic detection and feedback adjustment of the computer, the perfusate is maintained at a treatment temperature of 42.5 ° C for 60 minutes, and heat-sensitive chemotherapy drugs can be added to achieve the synergistic effect of chemotherapy drugs and hyperthermia, effectively killing free cancer cells or small implanted metastatic cancer lesions. Combined with surgery, it can treat or prevent tumor metastasis, and when used alone, it can effectively control cancerous effusion, improve patients' quality and time of life.
Learn moreGDHIPEC ·

Good Doctor · Hyperthermic Perfusion · Application Scenarios
Multiple cavities・Minimal damage・Control metastasis・Treat effusion
A hyperthermic perfusion chemotherapy machine equipment more suitable for applications in clinical departments




Holds more than 20 independent intellectual property rights
Keep abreast of market dynamics, focus on Good Doctor information
BLOG
The National Cancer Center has just released: 2024 National Cancer Report
Recently, with the approval of the National Health Commission, the National Cancer Center released the 2022 burden of malignant tumors in China based on the latest data from tumor registration and follow-up monitoring on JNCC. The results released this time are jointly calculated by the National Cancer Center and the International Agency for Research on Cancer (IARC), consistent with the Chinese data published by IARC in GLOBOCAN 2022 and released simultaneously.